This is a working overview of alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-06. Anything still debated is marked as such rather than presented as settled.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Despite being offered at other major Canadian restaurant chains, poutine (largely seen as Canada's signature dish), had never been a regular menu item at Tim Hortons. In June 2018, Tim Hortons introduced a limited time poutine across Canada, using seasoned potato wedges instead of the typical French fries. The poutine received mixed responses on social media. In Canada, the company began to offer hamburgers on the lunch menu in 2017. In an attempt to attract customers with a healthier option, Tim Hortons offered a hamburger filled with the "Beyond Meat" meatless option. The offering of hamburgers was risky for the company in their attempt to compete with the popular, large hamburger chains such as McDonald's. Wendy's and Burger King in Canada. Ironically, Burger King had acquired Tim Hortons in 2014 and was running it as a separate subsidiary and had supply chain mechanisms already in place to supply Tim Hortons with hamburger items. However, after only a brief period, consumers did not respond well to Tim Hortons offering of hamburgers or the "Beyond Meat" variety. With poor national sales, subsequently in 2019, hamburgers were removed from the menus at the Canadian Tim Horton's stores. On April 17, 2024, Tim Hortons introduced flatbread pizzas to expand on their lunch/dinner menu. The pizzas are available in four flavours: bacon everything, chicken parmesan, pepperoni, and simply cheese. The fifth flavour Spicy Rosé was introduced in October 2024.
In the 13th century, the category of reptile was recognized in Europe as consisting of a miscellany of egg-laying creatures, including "snakes, various fantastic monsters, lizards, assorted amphibians, and worms", as recorded by Beauvais in his Mirror of Nature. In the 18th century, the reptiles were, from the outset of classification, grouped with the amphibians. Linnaeus, working from species-poor Sweden, where the common adder and grass snake are often found hunting in water, included all reptiles and amphibians in class "III – Amphibia" in his Systema Naturæ. The terms reptile and amphibian were largely interchangeable, reptile (from Latin repere, 'to creep') being preferred by the French. J.N. Laurenti was the first to formally use the term Reptilia for an expanded selection of reptiles and amphibians basically similar to that of Linnaeus. Today, the two groups are still commonly treated under the single heading herpetology.
No cases of IGFBP3 gene deletion in humans have been reported, but mice lacking the gene show near-normal growth. IGFBP-3 exerts antiproliferative effects in many cell types by blocking the ability of IGF-1 and IGF-2 to activate the IGF1R (which stimulates cell proliferation). For example, in esophageal epithelial cells, responsiveness to IGF-1 stimulation is suppressed by secreted IGFBP-3 and restored when IGFBP-3 is downregulated by epidermal growth factor. IGFBP-3 can also inhibit cell function by mechanisms that are independent of effects on IGF1R signaling, even in cells that entirely lack IGF1R. IGF (or IGF1R) independent effects are commonly studied using mutant forms of IGFBP-3 with decreased IGF binding affinity. Thus, IGFBP-3-induced apoptosis in differentiating chondrocyte precursor cells is seen equally with a non-IGF binding IGFBP-3 mutant, demonstrating that the mechanism does not involve IGF binding. IGF1R-independent growth inhibition by IGFBP-3 may involve the induction of pro-apoptotic proteins such as Bax and Bad and may be mediated by ceramides (pro-apoptotic lipids), or potentiate ceramide action IGFBP-3 interaction with nuclear hormone receptors may also lead to inhibition of cell proliferation. Contrasting with the typical growth-inhibitory effects of IGFBP-3, stimulation of cell proliferation by IGFBP-3 has also been observed. This can occur either by enhancing IGF-stimulated proliferation or in the absence of IGF-1.
=== Zwitterion === Zwitterions contain an anionic and a cationic centre in the same molecule, but are not considered salts. Examples of zwitterions are amino acids, many metabolites, peptides, and proteins.
=== Asthma === Patients' response to inhaled corticosteroids has some basis in genetic variations. Two genes of interest are CHRH1 (corticotropin-releasing hormone receptor 1) and TBX21 (transcription factor T-bet). Both genes display some degree of polymorphic variation in humans, which may explain how some patients respond better to inhaled corticosteroid therapy than others. However, not all asthma patients respond to corticosteroids and large sub groups of asthma patients are corticosteroid resistant. A study funded by the Patient-Centered Outcomes Research Institute of children and teens with mild persistent asthma found that using the control inhaler as needed worked the same as daily use in improving asthma control, number of asthma flares, how well the lungs work, and quality of life. Children and teens using the inhaler as needed used about one-fourth the amount of corticosteroid medicine as children and teens using it daily.
Sources: en.wikipedia.org
In the 1980s, Mister Donut was the largest competitor to Dunkin'. On March 31, 1987, Elie G. Saheb and his business associates acquired the trademark rights for Mister Donut in the United Kingdom and afterwards opened a Mister Donut pilot store and bakery in Fulham, London. On May 2, 1988, the Mister Donut franchise sold the trademark rights for the European market at large. By the 1980s, Mister Donut had over 550 stores in the United States and Canada. In 1989, the British corporate giant Allied-Lyons plc acquired Dunkin' Donuts from Rosenberg for a reported £196 million. After becoming a subsidiary of Allied-Lyons, Dunkin' Donuts immediately acquired Mister Donut from International Multifoods. Mister Donut stores were offered the option to convert to Dunkin', while all remaining Mister Donut franchises in the rest of the world started being operated on their own such as in Japan and El Salvador. Mister Donut sold its Middle East trademarks on October 14, 1995. In July 2005, Allied-Lyons was acquired by Pernod Ricard SA. On December 12, 2005, Pernod Ricard announced that it had agreed to sell Dunkin' Brands, which owned Dunkin' and Mister Donut, to a consortium of three US private equity firms (Thomas H. Lee Partners, the Carlyle Group and Bain Capital LLP) for US$2.43 billion. The closing of the sale occurred on March 1, 2006. In August 2012, Dunkin' Brands became completely independent of the private equity firms. As of 2017, only one Mister Donut store remains in the United States, in Godfrey, Illinois (outside of St. Louis), while there were 10,000 stores worldwide.
Thy-1 membrane glycoprotein or CD90 (Cluster of Differentiation 90) is a protein that in humans is encoded by the THY1 gene. It is a 25–37 kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored conserved cell surface protein with a single V-like immunoglobulin domain, originally discovered as a thymocyte antigen. Thy-1 can be used as a marker for a variety of stem cells and for the axonal processes of mature neurons. Structural study of Thy-1 led to the foundation of the Immunoglobulin superfamily, of which it is the smallest member, and led to some of the initial biochemical description and characterization of a vertebrate GPI anchor and also the first demonstration of tissue specific differential glycosylation.
Np(VI) or NpO2+2, the neptunyl ion, shows a light pink or reddish color in an acidic solution and yellow-green otherwise. It is a strong Lewis acid and is the main neptunium ion encountered in solutions of pH 3–4. Though stable in acidic solutions, it is quite easily reduced to the Np(V) ion, and it is not as stable as the homologous hexavalent ions of its neighbours uranium and plutonium (the uranyl and plutonyl ions). It hydrolyzes in basic solutions to form the oxo and hydroxo ions NpO2OH+, (NpO2)2(OH)2+2, and (NpO2)3(OH)+5.
== Medical uses == Saxagliptin is used as monotherapy or in combination with other drugs for the treatment of type 2 diabetes. It does not appear to decrease the risk of heart attacks or strokes. One study showed a 3.5% risk of hospitalization for heart failure compared to 2.8% in a placebo-controlled group. Like other DPP-4 inhibitors, it has relatively modest HbA1c lowering ability, is associated with a relatively low risk of hypoglycemia, and does not cause weight gain. Saxagliptin improved mean HbA1c levels (relative to placebo) in a 24-week trial in people with type 2 diabetes. Combination therapy with saxagliptin and metformin was more effective than saxagliptin or metformin monotherapy. When the relative benefits of increasing the dose of a sulfonylurea or adding saxagliptin were assessed in a study of 768 patients, combination treatments were shown to have a significantly greater impact on fasting blood glucose than increasing the tested glibenclamide dose alone.
Sources: en.wikipedia.org
Jung decided that his near-psychotic experiences were of value and, in private, he induced hallucinations or, in his words, a process of "active imagination". He recorded everything he experienced in small journals, which Jung referred to in the singular as his Black Book, considering it a "single integral whole", even though some of these original journals have a brown cover. Jung described his 1912 book as "an attempt, only partially successful, to create a wider setting for medical psychology and to bring the whole of the psychic phenomena within its purview". The book was later revised and retitled Symbols of Transformation in 1952. The material Jung wrote was subjected to several edits, hand-written and typed, including another, "second layer" of text, his continual psychological interpretations during the process of editing. Around 1915, Jung commissioned a large red leather-bound book, and began to transcribe his notes and paint, working intermittently for sixteen years. Jung left no posthumous instructions about the final disposition of what he called the Liber Novus or Red Book. Sonu Shamdasani, a historian of psychology from London, tried for three years to persuade Jung's resistant heirs to have it published. Ulrich Hoerni, Jung's grandson who manages the Jung archives, decided to publish it when the necessary additional funds were raised through the Philemon Foundation. Up to September 2008, fewer than about two dozen people had ever seen it. In 2007, two technicians for DigitalFusion, working with New York City publishers W. W.
=== Western Docks === This part of the port is formed by the western arm of the harbour, Admiralty Pier, and its associated port facilities. Recently the focus of a £250 million port redevelopment project co-financed by the European Union.
=== Multi-parametric surface plasmon resonance === Multi-parametric surface plasmon resonance has been utilized to characterize both the thickness and refractive index of chemical-vapor-deposition (CVD)-grown graphene films. At a wavelength of 670 nm (6.7×10−7 m), measured refractive index and extinction coefficient values are 3.135 and 0.897, respectively. Thickness determination yielded 3.7 Å across a 0.5mm area, consistent with the 3.35 Å reported for layer-to-layer carbon atom distance of graphite crystals. This method is applicable for real-time label-free interactions of graphene with organic and inorganic substances. The existence of unidirectional surface plasmons in nonreciprocal graphene-based gyrotropic interfaces has been theoretically demonstrated, offering tunability from THz to near-infrared and visible frequencies by controlling graphene's chemical potential. Particularly, the unidirectional frequency bandwidth can be 1– 2 orders of magnitude larger than that achievable with metal under similar magnetic field conditions, stemming from graphene's extremely small effective electron mass.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.